Webcast ImageWebcast
scPharmaceuticals, Inc.at BMO Capital Markets Prescriptions for Success Healthcare Conference (Replay)
12/14/17 at 4:30 p.m. ET
scPharmaceuticals, Inc.at BMO Capital Markets Prescriptions for Success Healthcare Conference
Thursday, December 14, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014
scPharmaceuticals Inc. to Present at the BMO Capital Markets Prescriptions for Success Healthcare ConferenceBURLINGTON, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that Troy A. Ignelzi, chief financial officer of scPharmaceuticals, will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference at 4:30 PM ET on Thursday, December 14, 2017, at the […]
scPharmaceuticals Inc. Announces Closing of Over-Allotment Option in its Initial Public OfferingBURLINGTON, Mass., Nov. 29, 2017 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (the “Company” or “scPharmaceuticals”) (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced it has issued an additional 894,968 shares of common stock at the initial public offering price of $14.00, resulting in additional gross proceeds of approximat […]
scPharmaceuticals Inc. Announces Closing of Initial Public OfferingBURLINGTON, Mass., Nov. 29, 2017 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (the “Company”) a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced the closing of its initial public offering of 6,400,000 shares of common stock at a public offering price of $14.00 per share.  All of the shares sold in the offering were offered by scPharmaceutic […]
scPharmaceuticals Inc. Announces Pricing of Initial Public OfferingBURLINGTON, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (the “Company”) a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced the pricing of its initial public offering of 6,400,000 shares of common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions, for gross proceeds of $ […]
scPharmaceuticals Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide)BURLINGTON, MA, November 2, 2017 /PRNewswire/ — scPharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced that the 505(b)(2) New Drug Application (NDA) for Furoscix has been accepted for filing by the U.S. Food and Drug Administration (FDA). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set an action date o […]
John Tucker Appointed as Chief Executive Officer of scPharmaceuticalsLEXINGTON, MA, April 26, 2017 /PRNewswire/ — scPharmaceuticals, Inc., a    privately held biopharmaceutical company transforming patient care and healthcare    costs through innovative subcutaneous drug delivery, announced the appointment of    John Tucker as president and chief executive officer, effective immediately. Mr.    Tucker was also elected to the board of directors of scPharmaceuticals.    “John has both the strong leadership skills and the business expertise    requi […]
scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide ProductLEXINGTON, Mass., January 24, 2017 /PRNewswire/ – scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the start of the first phase of a study conducted by the Heart Failure Clinical Research Network (HFN). HFN is a clinical research initiative funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The primary goal of the HFN is to […]
scPharmaceuticals Announces Closing of $45.6 Million in Series B FinancingFunding supports preparation for commercial introduction of Furoscix™ and further advancement of the sc2Wear™ drug delivery platform. FOR IMMEDIATE RELEASE: Lexington, MA, January 4, 2017 — scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery announced today that it has closed a $45.6 million Series B investment round. The investment was co-led by OrbiMed and a wholly-owned subsidiary of Sun Pharmace […]